JP2019196384A5 - - Google Patents

Download PDF

Info

Publication number
JP2019196384A5
JP2019196384A5 JP2019133268A JP2019133268A JP2019196384A5 JP 2019196384 A5 JP2019196384 A5 JP 2019196384A5 JP 2019133268 A JP2019133268 A JP 2019133268A JP 2019133268 A JP2019133268 A JP 2019133268A JP 2019196384 A5 JP2019196384 A5 JP 2019196384A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
nucleotides
stretch
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019133268A
Other languages
English (en)
Japanese (ja)
Other versions
JP7086039B2 (ja
JP2019196384A (ja
Filing date
Publication date
Priority claimed from EP13004722.8A external-priority patent/EP2853595A1/en
Application filed filed Critical
Publication of JP2019196384A publication Critical patent/JP2019196384A/ja
Publication of JP2019196384A5 publication Critical patent/JP2019196384A5/ja
Application granted granted Critical
Publication of JP7086039B2 publication Critical patent/JP7086039B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019133268A 2013-09-30 2019-07-19 NOTCH 1特異的なsiRNA分子 Expired - Fee Related JP7086039B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13004722.8A EP2853595A1 (en) 2013-09-30 2013-09-30 NOTCH 1 specific siRNA molecules
EP13004722.8 2013-09-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016544736A Division JP6561061B2 (ja) 2013-09-30 2014-09-30 NOTCH 1特異的なsiRNA分子

Publications (3)

Publication Number Publication Date
JP2019196384A JP2019196384A (ja) 2019-11-14
JP2019196384A5 true JP2019196384A5 (https=) 2020-01-16
JP7086039B2 JP7086039B2 (ja) 2022-06-17

Family

ID=49304652

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016544736A Expired - Fee Related JP6561061B2 (ja) 2013-09-30 2014-09-30 NOTCH 1特異的なsiRNA分子
JP2019133268A Expired - Fee Related JP7086039B2 (ja) 2013-09-30 2019-07-19 NOTCH 1特異的なsiRNA分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016544736A Expired - Fee Related JP6561061B2 (ja) 2013-09-30 2014-09-30 NOTCH 1特異的なsiRNA分子

Country Status (16)

Country Link
US (2) US9896690B2 (https=)
EP (2) EP2853595A1 (https=)
JP (2) JP6561061B2 (https=)
CN (2) CN105814202B (https=)
AU (1) AU2014327809B2 (https=)
CA (1) CA2924788A1 (https=)
DK (1) DK3052625T3 (https=)
HR (1) HRP20211525T1 (https=)
HU (1) HUE056609T2 (https=)
IL (1) IL244661B (https=)
LT (1) LT3052625T (https=)
MX (1) MX377713B (https=)
RU (1) RU2651493C2 (https=)
SG (2) SG11201602437VA (https=)
SI (1) SI3052625T1 (https=)
WO (1) WO2015043768A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
CN115151644B (zh) * 2019-12-27 2024-06-21 国立大学法人神户大学 癌基因治疗药
CN112626068B (zh) * 2020-12-21 2021-12-03 徐州医科大学 一种靶向Notch1基因的LncRNA及其应用
CN116790603B (zh) * 2023-08-18 2023-10-31 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
AU3751299A (en) 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
SI1771206T1 (en) 2004-05-05 2018-06-29 Silence Therapeutics Gmbh Lipids, lipid complexes and use thereof
CN101981189A (zh) * 2008-01-29 2011-02-23 西马生物医学计划公司 能够以协同方式引起基因表达转录后沉默的方法和组合物
WO2009114726A1 (en) * 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising notch1 sirna and methods of use thereof
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
KR20140047141A (ko) * 2011-08-03 2014-04-21 쿠아크 파마수티칼스 인코퍼레이티드 청력 및 균형 장애를 치료하기 위한 이중-가닥 올리고뉴클레오티드 화합물들
EP2802657B1 (en) * 2012-01-12 2018-05-02 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules

Similar Documents

Publication Publication Date Title
JP2019196384A5 (https=)
US11583591B2 (en) Compositions and methods of treating muscle atrophy and myotonic dystrophy
JP2021531022A5 (https=)
JP2005512976A5 (https=)
JP7130639B2 (ja) 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用
JP2005506087A5 (https=)
US20210123060A1 (en) CONDITIONAL-siRNAS AND USES THEREOF IN TREATING ACUTE MYELOID LEUKEMIA
US11613750B2 (en) Methods of reducing virus molecule levels
WO2022129097A2 (en) Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
CN112996913A (zh) 寡聚核酸分子及其应用
JP2016533190A5 (https=)
TWI679023B (zh) 纖維化症預防或治療劑
AU2021296450A1 (en) Aptamers for personal health care applications
HRP20211525T1 (hr) Molekule sirna specifične za notch 1
JPWO2019193144A5 (https=)
US12409230B2 (en) Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy
EP4119164A1 (en) Anti-coronavirus effect and application of pi4k inhibitor
CN120272477A (zh) 靶向Zyx基因的小干扰RNA的应用
WO2017043639A1 (ja) キメラデコイ
JP2007517498A5 (https=)
JP2015507478A5 (https=)
EP4263834A1 (en) Aptamers for personal health care applications
Tomar et al. Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano-and cell-based intervention
CN106459970A (zh) 微rna146‑a及其于诊断、治疗及预防小核醣核酸病毒感染的用途及微rna146‑a拮抗剂
Eccleston Single-AAV-mediated base editor delivery